본문 바로가기

Model-Based Evaluation of HangAmDan-B1 and Afatinib Combination Therapy in HCC827 Xenograft Mice with Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
PHARMACEUTICALS18(5) · #748 · 2025
피인용
Web of Science 0Scopus 0
FWCI (Scopus)
0
JCR IF
JCR 2024 4.8
ISSN
1424-8247

저자

  1. Yang, Sung-yoon제1저자Chungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea
  2. Ngo, Lien ThiPHENIKAA Univ, Fac Pharm, Hanoi 12116, Vietnam
  3. Lee, SoyoungChungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea
  4. Yun, Hwi-yeolChungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea
  5. Bui, Tham ThiChungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea
  6. 김동현Pusan Natl Univ, Korean Med Hosp, Dept Internal Med, Yangsan 50612, South Korea
  7. Chae, Jung-woo교신저자Chungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea
  8. 박소정교신저자Pusan Natl Univ, Korean Med Hosp, Dept Internal Med, Yangsan 50612, South Korea

초록

Objectives: HangAmDan-B1 (HAD-B1), a blended herbal mixture, has been investigated as an adjuvant therapy with afatinib (AFT) to treat non-small lung cancer (NSCLC). Although preclinical studies demonstrated promising synergistic results, clinical trials have not yet confirmed the expected benefits. This study aims to quantitatively examine the exposure-response relationship and synergistic interactions through pharmacokinetic/pharmacodynamic (PK/PD) modeling. Methods: A PK/PD model was established and validated based on tumor growth profiles from a xenograft mouse study of gefitinib-resistant HCC827. Model-based simulations were performed to predict and assess therapeutic effects across different treatment groups. Results: The PK/PD model confirmed HAD-B1 enhances the potency of AFT by 1.45-fold. Model-based simulations predicted that combination treatment maintains a lower tumor size compared to AFT monotherapy. Conclusions: This study quantitatively demonstrated the synergistic interaction between HAD-B1 and AFT. The developed PK/PD model provides insights into potential dosing strategies to treat NSCLC resistant to EGFR-TKIs. Further clinical trials are warranted to validate these findings and refine dosing strategies to improve therapeutic outcomes.

키워드

pharmacokinetic/pharmacodynamic modelingafatinibhangamdan-B1non-small cell lung cancerEGFR-TKI resistancedrug-drug interactionsCELL LUNG-CANCEREGFR-TKIPHARMACOKINETICS

식별자

Scopus EID
2-s2.0-105006722731
WoS UID
001495716800001